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Background. The purpose of the study was to evaluate the correlation between the maximum standardized uptake 
value (SUVmax), size of primary lung lesion, disease-free survival (DFS) and overall survival (OS) in patients with stage I 
and II non-small cell lung cancer (NSCLC) in 2 years follow-up.
Patients and methods. Forty-nine patients with stage I-II NSCLC were included in this study. Pre-surgical 2-deoxy-
2-[18F]fluoro-D-glucose positron-emission tomography (18F-FDG PET/CT) study was performed for all patients. The 
relationship between SUVmax, tumour size and clinical outcome was measured. The cut-off value for SUVmax and 
tumour size with the best prognostic significance, probability of DFS and the correlation between SUVmax and the 
response to therapy were calculated.
Results. There was a statistically significant correlation between SUVmax and DFS (p = 0.029). The optimal cut-offs were 
9.00 for SUVmax (p = 0.0013) and 30mm for tumour size (p = 0.0028). Patients with SUVmax > 9 and primary lesion size > 
30 mm had an expected 2years-DFS of 37.5%, while this rose to 90% if the tumour was <30 mm and/or SUVmax was <9.
Conclusions. In stage I-II, SUVmax and tumour size might be helpful to identify the subgroup of patients with high 
chance for recurrence.
Key words: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography; non-small cell lung cancer; maximum 
standardized uptake value; disease-free survival; overall survival. 
Introduction
Lung cancer (LC) is the major cause of death in the 
developing countries, with an incidence of about 
65-70 new cases per 100.000.1 2-deoxy-2-[18F]
fluoro-D-glucose positron-emission tomography 
(18F-FDG PET/CT) is widely used in lung cancer for 
staging, restaging and evaluation of the treatment 
response.2,3 Multiple studies demonstrate that PET/
CT is more sensitive and specific than PET alone in 
evaluating the lung cancer since it provides com-
bined morphological and functional information of 
the tumour.4-7 High accuracy of PET/CT has been 
observed in the early assessment of response to 
therapy, showing a close correlation between the 
reduction of tumour metabolic activity measured 
after a course of therapy and the clinical outcome 
of patients after the previewed cycles of therapy 
in patients in advanced stage.8-9 In early stage, 
Tumour Node Metastasis (TNM) staging system, 
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it is still the most reliable prognostic factor to pre-
dict the outcome after surgery. However, many pa-
tients in stage I or II may experience a worse out-
come than expected and an early relapse even after 
a successful tumour resection.10 Also magnetic res-
onance imaging (MRI) 11, computed tomography 
(CT) 12 and endobronchial ultrasonography (EBUS) 
13 have a role in the staging of lung cancer but, un-
like PET/CT, lack in providing functional infor-
mation, which may provide clinicians additional 
prognostic indications regarding the survival and 
the estimate risk of relapse by means of the assess-
ment of the maximum standardized uptake value 
(SUVmax).
The aim of this study was to estimate the cut-off 
value for combined SUVmax and size of primary 
lung lesion that correspond with poor disease-free 
survival (DFS) in patients with stage I and II non-
small cell lung cancer (NSCLC) in 2 years follow-up.
Patients and methods 
Between 2004 and 2009, forty-nine patients (36 
males = 73%; 13 females = 27%; M/F Ratio = 2.77:1; 
mean age = 67.2 years; range = 44-79 years) were 
referred to Positron Emission Tomography Centre 
IRMET S.p.A., Euromedic inc. in Turin, Italy 
and Unit of Nuclear Medicine of La Maddalena 
Hospital in Palermo, Italy for the evaluation of 
their non-small cell lung cancer. According to the 
inclusion criteria 49 patients included in this study 
received a complete tumour resection and system-
atic lymph node dissection.
All patients have been staged according to TNM 
7th edition.14 Survival and death information were 
obtained from the hospitals databases and through 
phone calls to the patient families. The research 
proposal was approved by Institutional Review 
Board and Ethics Committee.
The inclusion criteria were histologically proven 
NSCLC, glycaemia lower than 140 mg/dl at the 
time of the exam, availability of pre-surgical FDG-
PET/CT and tumour size > 20 mm to minimize the 
underestimation of SUV. Exclusion criteria were as 
follows: (a) poor performance status; (b) diabetes 
(due to poor uptake of FDG); (c) pregnancy; (d) 
Charlson Combined Age-Comorbidity Index ≥ 6; 
(e) histological diagnosis of “bronchioloalveolar 
cell carcinoma” (BAC) subtype.
Preoperative TNM staging was obtained via in-
formation gathered through patient’s chart includ-
ing physical examination, routine blood test, bron-
choscopy, contrast-enhanced CT of the chest and 
upper abdomen, brain CT and total-body 18F-FDG 
PET/CT scan. 
The PET/CT images were acquired using in-
tegrated PET/CT scanner (Discovery ST, General 
Electric Medical System, Milwaukee, WI, USA), 60 
minutes after the injection of the 260-420 MBq of 
18F-FDG, following 6 hours of fasting from the cra-
nial base to the pelvis (total body) in 3D modality. 
Blood glucose was measured before the injection of 
the tracer to ensure glucose blood levels < 140 mg/dL. 
The PET images were reconstructed iteratively on 
a 128 × 128 matrix. The SUVmax, within a spheri-
cal region of interest encompassing the entire vol-
ume, was calculated using a dedicated worksta-
tion (Xeleris, General Electric medical Systems, 
Milwaukee, WI, USA). The formula used for SUV 
calculation was: activity (MBq/ml) x body weight / 
injected dose (MBq/ml). The anatomical size of lung 
lesion was measured considering the maximum di-
ameter of the lesion in the three planes on CT.15 
PET, CT, and fused PET/CT images were re-
viewed, by two experienced nuclear medicine 
physicians. Images were assessed visually and 
semi-quantitatively. Patients were followed up for 
24 months with a frequency of clinical examination 
of every 3 months during the first year and every 
6 months in the second year. A contrast-enhanced 
CT scan of the thorax was performed in all cases 
at 6 and 12 months, while the additional PET/CT 
scans were used in case of suspected morphologi-
cal findings. 
The overall survival (OS) was calculated. The 
disease-free survival (DFS) was considered as the 
time between surgery and recurrence of disease. 
The correlation between SUVmax and clinical out-
come (2 years-DFS) was assessed by the Student-t 
test (the hypothesis was considered significant if p 
</= 0.05). The chi-square test was used to identify 
the SUVmax cut-off value at the time of the initial 
staging with the best correlation to prognosis. 
TABLE 1. Characteristics of population
Number of Patients 49
Sex 36 M 13 F
Mean Age 67.2 y (range: 44-79)
Histotypes:
Adenocarcinoma 28
Squamous 15
Large cell 2
Undetermined 4
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Finally, the estimated probability of disease-
free time according to the SUVmax cut-off and the 
dimensional threshold was calculated using the 
Kaplan-Meier method. 
Results
Twenty-eight out of 49 patients (M = 36, F = 13, M/F 
Ratio = 2.77: 1; mean age = 67.2 years, range: 44–79) 
diagnosed with adenocarcinoma (BAC excluded 
according to exclusion criteria) which was the 
most frequent tumour histologic subtype (57%). 
Squamous cell carcinoma was observed in 15 pa-
tients (31%), and large cell carcinoma in 2 cases 
(4%). In 4 patients (8%) no sufficient data about 
pathological examination were available and they 
were classified as undetermined (Table 1). 
At the time of the pre-surgical PET/CT scan, the 
patients in stage I-II showed an average SUVmax 
value of 10 ± 5.5 and an average size of primary 
lung lesion of 33 mm ± 17.00; at the follow-up pe-
riod of 24 months, DFS and OS were respectively 
73.4% and 83,6 %. 36 patients (average SUVmax 
value of 8.96 ± 5.26; mean size of primary lung le-
sions of 31.27 mm ± 18.65) were 2 years disease-free 
and presented an OS of 100%. 13 patients (average 
SUVmax = 12.8 ± 5.3; mean size of primary lung 
lesion = 40.5 ± 9.4 mm) had recurrence of disease 
(median DFS = 10 months, OS = 39.5%). There 
was a statistically significant correlation between 
SUVmax and DFS (p = 0.029, Student-t test). Using 
TABLE 2A. Summary of (stage I-II) patients’ outcome at a 
follow-up period of 24 months 
DFS 36 disease free 13 recurrence of disease
OS 41 alive  8 dead
TABLE 2B. Stratification of disease-free survival for the maximum 
standardized uptake value (SUVmax) cut-off at a follow-up 
period of 24 months. (Chi-square test) p = 0.0013
DFS SUVmax < 9 SUVmax > 9
Disease-free 26 10  
Recurrence of disease 2  11 
TABLE 2C. Stratification of disease-free survival for a size 
threshold of 30 mm at a follow-up period of 24 months. (Chi-
square test) p = 0.0028
DFS Size < 30 mm Size > 30 mm
Disease-free 22 14 
Recurrence of disease 1 12 
TABLE 2D. Stratification of disease-free survival for the combined 
maximum standardized uptake value (SUVmax) and size cut-offs 
at a follow-up period of 24 months. (Chi-square test) p = 0.0003
DFS
SUV max < 9 
and/or  
Size < 30 mm
SUV max > 9 
and  
Size > 30 mm
Disease-free 30 6 
Recurrence of disease 3 10 
FIGURE 1. Disease-free survival (DFS) curves (Kaplan-Meier) based on a dimensional 
cut-off of 30 mm. The disease-free survival curves illustrate that patients with a lung 
cancer with dimension < 30 mm present a better prognosis (significant longer DFS) 
than patients with lung cancer size > 30 mm.
Dashed line = DFS for patients in stage I-II with lesion diameter < 30 mm. 
Continuous line = DFS for patients in stage I-II with lesion diameter > 30 mm.
FIGURE 2. Disease-free survival (DFS) curves (Kaplan-Meier) based on a cut-off 
maximum standardized uptake value (SUVmax) of nine. The disease-free survival 
curves illustrate that patients with lung cancer SUVmax < 9 present a significant 
longer DFS than patients with lung cancer SUVmax > 9.
Dashed line = DFS for patients in stage I-II with SUVmax < 9; 
Continuous line = DFS for patients in stage I-II with SUVmax > 9. 
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the chi-square test, the SUVmax cut-off and the 
dimensional cut-off with the best prognostic sig-
nificance were 9.00 (p = 0.0013) and 30 mm (p = 
0.0028) respectively. In the subgroup of 26 patients 
presenting with a primitive lung lesion larger than 
30 mm, there were 12 recurrence of disease events 
(Table 2A-D), 2 of them with a SUV max <9 and 10 
of them with a SUV max > 9. 
Combining metabolic and dimensional pa-
rameters, patients with SUV > 9 and primary le-
sion size >30 mm had an expected 2 years-DFS of 
37.5%, while the expected 2 years-DFS raised to 
90% if the tumour was smaller than 30 mm and/or 
the SUVmax was below 9.00 (one or both cut-offs) 
(Table 2A-D).
With cut-off values (SUVmax = 9, size = 30 mm) 
and using the univariate statistical analysis accord-
ing to the Kaplan-Meier method, two different dis-
ease-free survival curves were generated (Figures 1, 
2). The analysis of the disease-free survival curves 
illustrated that patients with SUVmax < 9 and pa-
tients with a primary lung cancer size below 30 mm 
demonstrated a significant longer DFS (Figure 3A,B) 
in comparison with patients with SUVmax > 9 or pa-
tients with a primitive lesion > 30 mm.
Discussion
Among several prognostic staging systems of 
NSCLC, the TNM system still remains the most 
widely used. Despite this, the clinical outcome 
doesn’t always follow the clinical prognostic as-
sessment, so the disease can sometimes result in 
more unfavorable outcome than expected.2,16 Even 
if a complete surgical resection is accomplished, 
NSCLCs can relapse. These data are extremely 
dramatic in patients in stage I and II, in whom re-
currences of disease will happen and a more ag-
gressive treatment would have been beneficial.2 In 
NSCLC, the use of SUV measurements previously 
reported to be accurate and reproducible in the as-
sessment of the outcome.17-22
In our study with patients in stage I-II it has been 
attempted to focus on the prognostic significance of 
SUVmax and dimensional parameter of the primi-
tive neoplastic lung lesion in reference with the 2 
years disease-free survival. In the present study we 
accurately selected patients undergoing only the 
surgical procedure. The cut-off value of a SUVmax 
in a 2 years follow-up period has not been clearly 
defined in literature.23-28 Jeong et al. determined a 
cut-off value of 7 to be indicator of poor disease-free 
survival (DFS) 24, while Goodgame and colleagues 
found the threshold value of SUV to be 5.5.12 Our 
data showed that in stages I and II, the increased 
size more than threshold (30 mm) and SUVmax 
cut-off (9.00) could help to identify a subgroup 
of patients with a high risk of recurrence within 2 
years after curative surgery. The relative estimated 
risk for patients with SUVmax < 9 and/or tumour 
size < 30 mm is lower (10%) (p = 0.004) compared 
to the group above these cut-offs. Similar results 
had been documented by the Leuven Lung Cancer 
Group which reported a 2-year survival rate of 86% 
if the resected tumour was smaller than 3 cm and 
the SUV was below 7.27
FIGURE 3B. Post-surgical 18F-FDG PET/CT axial images. No pathological 18F-FDG 
uptake can be detected in the perihilar region of the right lung.
FIGURE 3A. Pre-surgical 18F-FDG PET/CT axial images. Abnormal 18F-FDG uptake 
(SUVmax < 9) in a cancer lesion located in the perihilar region of the right lung 
(size < 30 mm). 
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Our data showed that, in the early stages of dis-
ease, SUVmax and dimension of the primitive le-
sion were independent prognostic factors and this 
correlated with 3 previously published papers.11,25,28 
In our series, the additional prognostic information 
provided by the SUVmax cut-off showed the most 
powerful impact in case of tumour > 30 mm. In 
fact the highest rate of recurrence (62.5%) was re-
corded in case of tumour SUVmax >9 and size >30 
mm (10 recurrence of disease and 6 disease-free 
patients), while patients with SUVmax <9 and tu-
mour dimension >30 mm, presented a lower rate of 
recurrence (20%; 8 disease –free and 2 recurrence of 
disease events). However, due to the small number 
of patients it was not possible to attempt to demon-
strate any statistical correlation.
Our study, however, had several limitations in-
cluding a limited number of patient, lack of SUV 
quantification in each single histotype, and dif-
ferent cut off value for each subtype of NSCLC. 
Additional studies are required to further accu-
rately assess the correlation between SUVmax and 
size of primary lung lesion with DFS and OS in dif-
ferent histotypes in 2 years period.
Conclusions
Our data suggested that in patients with NSCLC 
stage I-II the combination of a dimensional cut-off 
(30 mm) and of a SUVmax cut-off (9) could identify 
a subgroup of patients that would have a high risk 
of recurrence of disease within 2 years from surgery.
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